Wird geladen...
Learning from the past to design better trials in second-line treatment for mesothelioma patients
Malignant pleural mesothelioma (MPM) is an aggressive cancer characterised by modest sensitivity to systemic chemotherapy. The standard treatment remains platinum-based chemotherapy with pemetrexed. Recently, the addition of an antiangiogenic drug, bevacizumab, to first-line chemotherapy has been sh...
Gespeichert in:
| Veröffentlicht in: | Ecancermedicalscience |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Cancer Intelligence
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6345074/ https://ncbi.nlm.nih.gov/pubmed/30679948 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2018.881 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|